Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.94 |
| ▸ | MAPT | P10636 | 3/20 | 0.94 |
| ▸ | HPGD | P15428 | 3/20 | 0.94 |
| ▸ | GLA | P06280 | 2/20 | 0.94 |
| ▸ | ACHE | P22303 | 1/20 | 0.94 |
| ▸ | HTR3A | P46098 | 1/20 | 0.62 |
| ▸ | NQO2 | P16083 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acridine SCHEMBL31147979 | 1.00 | ALDH1A1 (0.94) | ALDH1A1MAPTHPGDGLAACHE | |
| Acridine SCHEMBL6427751 | 1.00 | ALDH1A1 (0.94) | ALDH1A1MAPTHPGDGLAACHE | |
| Acridine SCHEMBL28062881 | 0.97 | MAPT (0.88) | ALDH1A1MAPTHPGDGLAACHE | |
| Acridine SCHEMBL4972293 | 0.97 | ALDH1A1 (1.00) | ALDH1A1MAPTHPGDGLAACHE | |
| Acridine SCHEMBL3045498 | 0.97 | ALDH1A1 (1.00) | ALDH1A1MAPTHPGDGLAACHE | |
| Acridine SCHEMBL1772714 | 0.97 | ALDH1A1 (1.00) | ALDH1A1MAPTHPGDGLAACHE | |
| Acridine SCHEMBL8339 | 0.97 | ALDH1A1 (1.00) | ALDH1A1MAPTHPGDGLAACHE | |
| Acridine SCHEMBL29352289 | 0.97 | ALDH1A1 (1.00) | ALDH1A1MAPTHPGDGLAACHE | |
| Anthracene SCHEMBL9879830 | 0.94 | MAPT (0.94) | ALDH1A1MAPTHPGDGLAACHE | |
| Acridine SCHEMBL1551975 | 0.94 | ALDH1A1 (0.94) | ALDH1A1MAPTHPGDGLAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2774625-B1 | POLYMER-TYPE FLUORESCENT MOLECULE PROBE | MAEDA HIROSHI (JP) | 2017-04-12 | — | — | EP | claimed |
| CN-104230927-B | Aza-acridine ammonia derivative, preparation method and the application thereof of one class dibit point acetylcholine esterase inhibition activity | HENAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE (CN) | 2016-05-11 | — | — | CN | claimed |
| CN-102365024-A | Compounds, compositions and methods for preventing metastasis of cancer cells | AKEBIA THERAPEUTICS INC | 2012-02-29 | — | — | CN | claimed |
| CN-101460060-A | Compositions and methods for topical treatment of tar-responsive skin disorders | TRISTRATA INC (US) | 2009-06-17 | — | — | CN | claimed |
| CN-1960735-A | Use of pharmaceutical combinations for the treatment of insulin resistance | DIAMEDICA INC (CA) | 2007-05-09 | — | — | CN | claimed |
| CN-1726033-A | Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds | PHARMACIA & UPJOHN CO LLC (US) | 2006-01-25 | — | — | CN | claimed |
| US-20050245504-A1 | Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds | CORBETT JEFFREY W | 2005-11-03 | — | — | US | claimed |
| EP-1572205-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | Pharmacia & Upjohn Company LLC (US) | 2005-09-14 | — | — | EP | claimed |
| WO-2004052348-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | claimed |
| EP-0328535-B1 | THE ADMINISTRATION OF MONOAMINE ACRIDINES IN CHOLINERGIC NEURONAL DEFICIT STATES | SUMMERS WILLIAM KOOPMANS (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0595365-A1 | Pharmaceutical composition for the treatment of underlying nonpharmacologically induced nervous system cholinergic deficit state comprising monoamine acridine derivatives | Summers, William Koopmans (US) | 1994-05-04 | — | — | EP | claimed |
| EP-0328535-A4 | THE ADMINISTRATION OF MONOAMINE ACRIDINES IN CHOLINERGIC NEURONAL DEFICIT STATES | — | 1991-05-22 | — | — | EP | claimed |
| EP-0328535-A1 | THE ADMINISTRATION OF MONOAMINE ACRIDINES IN CHOLINERGIC NEURONAL DEFICIT STATES. | SUMMERS WILLIAM KOOPMANS | 1989-08-23 | — | — | EP | claimed |
| US-4816456-A | Administration of monoamine acridines in cholinergic neuronal deficit states | SUMMERS WILLIAM K (US) | 1989-03-28 | — | — | US | claimed |
| WO-1988002256-A1 | THE ADMINISTRATION OF MONOAMINE ACRIDINES IN CHOLINERGIC NEURONAL DEFICIT STATES | SUMMERS WILLIAM KOOPMANS (US) | 1988-04-07 | — | — | WO | claimed |
| CN-118791446-A | Preparation method of promethazine hydrochloride | 遂成药业股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| WO-1988002256-A1 | THE ADMINISTRATION OF MONOAMINE ACRIDINES IN CHOLINERGIC NEURONAL DEFICIT STATES | SUMMERS WILLIAM KOOPMANS (US) | 1988-04-07 | — | — | WO | disclosed |
| WO-1988002256-A1 | THE ADMINISTRATION OF MONOAMINE ACRIDINES IN CHOLINERGIC NEURONAL DEFICIT STATES | SUMMERS WILLIAM KOOPMANS (US) | 1988-04-07 | — | — | WO | disclosed |
| WO-1988002256-A1 | THE ADMINISTRATION OF MONOAMINE ACRIDINES IN CHOLINERGIC NEURONAL DEFICIT STATES | SUMMERS WILLIAM KOOPMANS (US) | 1988-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245504-A1 | Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds | CHRNA7, CHRNG, CHRNE | ALDH1A1 2823/4885MAPT 322/4885HPGD 2008/4885 |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | ALDH1A1 1959/4885MAPT 69/4885HPGD 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.